Tien Liang BioTech Co., Ltd.
TPEX:4127 Stock Report
Tien Liang BioTech Balance Sheet Health
Financial Health criteria checks 6/6 Tien Liang BioTech has a total shareholder equity of NT$474.2M and total debt of NT$105.0M, which brings its debt-to-equity ratio to 22.1%. Its total assets and total liabilities are NT$652.4M and NT$178.2M respectively. Tien Liang BioTech's EBIT is NT$10.1M making its interest coverage ratio 10.2. It has cash and short-term investments of NT$189.4M.
Key information
22.1%
Debt to equity ratio
Interest coverage ratio 10.2x Cash NT$189.45m Equity NT$474.18m Total liabilities NT$178.21m Total assets NT$652.39m
Recent financial health updates
Show all updates
Now 22% overvalued after recent price rise Oct 25
Now 22% overvalued Aug 28
Upcoming dividend of NT$0.50 per share Aug 20
Second quarter 2024 earnings released: NT$0.08 loss per share (vs NT$0.12 profit in 2Q 2023) Aug 17
First quarter 2024 earnings released: EPS: NT$0.17 (vs NT$0.14 in 1Q 2023) May 19
Investor sentiment deteriorates as stock falls 17% Apr 23
Full year 2023 earnings released: EPS: NT$39.00 (vs NT$1.30 in FY 2022) Apr 02
New minor risk - Share price stability Mar 22
Investor sentiment improves as stock rises 22% Mar 19
Tien Liang BioTech Co., Ltd., Annual General Meeting, Jun 28, 2024 Mar 14
Third quarter 2023 earnings released: NT$0.03 loss per share (vs NT$0.20 profit in 3Q 2022) Nov 15
Second quarter 2023 earnings released: EPS: NT$0.12 (vs NT$0.22 in 2Q 2022) Aug 11
Third quarter 2022 earnings released: EPS: NT$0.20 (vs NT$0.45 in 3Q 2021) Nov 16
Third quarter 2022 earnings released: EPS: NT$0.20 (vs NT$0.45 in 3Q 2021) Nov 13
Investor sentiment deteriorated over the past week Jul 04
Investor sentiment improved over the past week Jun 06
Investor sentiment improved over the past week Apr 18
Full year 2021 earnings released: EPS: NT$1.02 (vs NT$1.13 loss in FY 2020) Mar 30
Second quarter 2021 earnings released: EPS NT$0.26 (vs NT$0.39 loss in 2Q 2020) Aug 18
First quarter 2021 earnings released: NT$0.26 loss per share (vs NT$0.045 loss in 1Q 2020) May 17
Is Tien Liang BioTech (GTSM:4127) Using Too Much Debt? Apr 19
Full year 2020 earnings released: NT$1.13 loss per share (vs NT$1.02 loss in FY 2019) Mar 31
New 90-day low: NT$10.55 Jan 20
Tien Liang BioTech (GTSM:4127) Is Carrying A Fair Bit Of Debt Jan 04
Third quarter 2020 earnings released: NT$0.40 loss per share Nov 14
New 90-day low: NT$10.60 Oct 15
New 90-day low: NT$10.80 Sep 30
New 90-day low - NT$11.45 Sep 14
First half earnings released Aug 16
Financial Position Analysis
Short Term Liabilities: 4127's short term assets (NT$312.0M) exceed its short term liabilities (NT$144.1M).
Long Term Liabilities: 4127's short term assets (NT$312.0M) exceed its long term liabilities (NT$34.1M).
Debt to Equity History and Analysis
Debt Level: 4127 has more cash than its total debt.
Reducing Debt: 4127's debt to equity ratio has reduced from 32.2% to 22.1% over the past 5 years.
Debt Coverage: 4127's debt is well covered by operating cash flow (58.7%).
Interest Coverage: 4127's interest payments on its debt are well covered by EBIT (10.2x coverage).
Discover healthy companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
